Blue Horseshoe Stocks: APHA, MDCA & More

Aphria, Inc. APHA

Yesterday morning in our premarket report, we said that the unusually high short interest in APHA was one of the factors playing into our decision to designate it as a bottom-watch play. The rebound we were looking for came instantaneously for us with APHA heating up, and the short squeeze was on.

From a low of 3.75, the stock cruised on up to a high of 5.59 for a daily burst amounting to 49% on considerable volume. We’ll be looking for APHA to continue to make up some of the ground it has lost over the past month.



MDC Partners, Inc. MDCA

Another stock we included as a bottom play yesterday, MDCA also experienced a solid performance on the day. It traded from a low of 2.57 on up to 3.29, for a moderate but respectable 28% gain.

It also factored in as the NASDAQ’s fourth largest gainer of the session. The run came to an end right around an area of previous resistance, so we’ll look for it to break that top in the sessions ahead.



Fresh Options Ideas

Cronos Group Inc. CRON Weekly $13-15 Calls* – As we were just mentioning on Tuesday, we first tagged CRON back on Halloween, at which time the stock was trading at a low of 7.10. This morning in the premarket the stock has attained an impressive new high of 14.58, marking a five week run of 105% The above mentioned calls are how we’re going to attempt to take advantage of today’s new movement on the chart.

Lululemon Athletica, Inc. LULU Weekly $130-133 Calls*

SDPR S&P 500 ETF (SPY) Weekly $268-270 Calls*

*Caution: NEVER trade options contracts with a weekly expiration on a Friday unless you are an expert level trader with disposable funds!


Extended Watchlist:
SGSI, DNR, NOG, RIG, OMED, WTI, WLL, CRC, CASI, KTOS

Blue Horseshoe Stocks: INFI Review & More

Infinity Pharmaceuticals, Inc. INFI

The stock with the most notable performance from yesterday morning’s watchlist was definitely INFI, which began trending up in the premarket, and continued its climb throughout the entire session.

The stock traded up from a low of 2.44 to 3.75, which works out to an intraday rise of 54% and it came on roughly 38X its monthly average volume. An early pullback from profit taking this morning would be a likely scenario, but if INFI can find support at a higher point than yesterday’s low, from



AcelRx Pharmaceuticals, Inc. ACRX

After the FDA’s rejecion of the company’s ‘Dsuvia” opioid painkiller, ACRX took a monstrous pounding yesterday down to its lowest price in three months.

As you can see on the chart, it fell all the way down to an area of support it had established back in July. We’ll be interested to monitor this play for a bottom, which could come at any time. Moves generated by FDA news, whether positive or negative, tend to be over-exaggerated and are almost always followed by a course correction.


Inotek Pharmaceuticals Corp ITEK

Here we have an example of being extremely ‘early to the party’ as we sometimes say. We alerted on ITEK back in July, after which point it saw a low of .89. It mostly traded sideways throughout the remainder of the summer, but recently began quite an impressive climb.

This morning, the stock hit news highs of 4.15 in premarket trading on news of a proposed merger with a clinical stage gene therapy company. It may have took a few months to realize, but it works out to an increase of 366%

For an added angle going forward, we’ll also signal the ITEK 10/20 $2.50 Calls for possible daytrades and/or swing trades into next week, and the 11/17 $2.50 & $5.00 Calls for a longer term idea.


Extended Watchlist:
SONS, MARK, HSC, DPW, AKS, CLF, RIG, ATNM, MGEN

Blue Horseshoe Stocks: KMX Recap & More

CarMax, Inc. KMX 

First up this morning, we’re going to start off the fresh trading week by reviewing the performance of the CarMax options we signaled in Friday’s premarket report on the heels of the company’s Q2 earnings beat.

We’re constantly pounding the table on post-earning options trading, simply because we are so very often successful in our selections. Volatility is a swing trader’s best friend, and few things create it more quickly and effectively than a solid beat on earnings.

So we signaled our interest in tracking the KMX Weekly $69.50-71.50 Calls and it worked like a charm:

$69.50 Calls - Range: 1.21-4.96 – Max Gain: 310%
$70 Calls – Range: 1.10-4.40 – Max Gain: 300%
$70.50 Calls – Range: .55-3.78 – Max Gain: 587%
$71 Calls – Range: .35-3.50 – Max Gain: 900%
$71.50 Calls – Range: .30-2.41 – Max Gain: 703%



Helios and Matheson Analytics, Inc. HMNY

We just updated our readers on our coverage of HMNY last Wednesday, when we pointed out that we slated the stock for tracking on August 15th and observed a subsequent low of 2.42. By midweek the stock had already made a considerable move up, but Friday’s session brought another big pop to new highs.

HMNY traded in a daily range from 5.67 to 7.95 gaining 40%, a very respectable intraday move in and of itself. The new high marked an overall move of 229% from our observed low.

Volume was much higher than average all last week, and the stock maintain roughly half of its daily advance into a fairly strong close, so we’ll need to keep monitoring HMNY for the continued establishment of higher highs and higher lows.


Extended Watchlist:
BYOC, ACER, IZEA, RIG, ARDM, INFI, IDXG

Blue Horseshoe Stocks: IDXG Update & More

Interpace Diagnostics Group, Inc. IDXG

We tracked IDXG last week over a couple of stellar sessions that led to a swing of more than 400%, cautioning that a dip-and-rip could be in the cards after seeing such a volatile move to the upside.

That’s exactly what we’ve seen in the past couple of days, as IDXG came down to find support at the .865 level, and in the ensuing three sessions it’s been steadily registering higher highs and higher lows, getting back to 1.25 yesterday (+45%).

We’ll continue to follow this story, which kicked off with the revelation that Aetna would cover Interpace’s ThyraMir™ test for its 46 million insured members. (>>View PR)


Experience Art & Design, Inc. EXAD

We had EXAD tagged in yesterday’s premarket report and this subpenny play produced a moderate run to kick off the session, even as the larger markets were struggling with the Fed rate hike announcement.

From an early low of .0023, the stock took just the first hour of trading to find its way up to a high of .0038, for a 65% pop. IDXG hung around that level until around lunchtime, and it did come back down to its daily low toward the close, so we’ll be looking for the possibility of a rebound.


Catalyst Biosciences, Inc. CBIO

We’re also interested in following the activity of CBIO today, which is gapping up in the premarket to the tune of more than 100% and looks like it could be lining up to have a big day. We’ll want to make sure it holds above its 50DMA (.80) on any pullbacks, but if it can breach past its 200DMA of 1.31, things could get very interesting.

News broke yesterday via an 8-K filing that CBIO had entered into a definitive agreement with Wyeth LLC, (wholly-owned subsidiary of Pfizer Inc.) to transfer exclusive rights to research, develop, manufacture and commercialize Factor VIIa variants, CB 813a and CB 813d, as well as transferring the investigational NDA to CBIO as well. (>>View Filing)



Fresh Options Idea: 
Transocean, Inc. RIG $15 and $14.50 Puts


Extended Watchlist:
VCEL, NWBO, BCLI, BPMX, DLOV, PPMT

Blue Horseshoe Stocks: TWTR Options & More

Globus Maritime, Ltd. GLBS

We included GLBS as a part of our extended watchlist yesterday after noticing that the stock had produced a solid session on Tuesday. Our hunch that the run could continue proved to be good, as the stock posted another nice intraday performance.

GLBS traded in a range from a low of 5.122 to a high of 8.769, a move of 71% and it came on more than seven times the monthly average volume. We’ll keep a slot on our watchscreens reserved for GLBS in the event it maintains its upward momentum and strings together a multi-day run.


Agora Holdings, Inc. AGHI

We’ve continued to follow AGHI as it has seen some consolidation over the past few sessions, and the lower it has crept, the more attractive it has begun to look as a bounceplay opportunity.

If you notice on the included chart, the stock has a recent track record of making a serious run-up from current PPS levels. The last time it traded below a dime, that was followed by a huge pop to more than .20. That’s just the kind of rebound we’ll be looking for as the stock searches for support.



Twitter, Inc. TWTR – Options Idea

In conjunction with buyout rumors that have been swirling around Twitter, we happen to like the look of the present chart, and thus we’d like to formulate a corresponding options idea. We’ve had a reasonable amount of success with the TWTR options chain in the past, and current conditions seem favorable enough to signal an extended-term idea today.

We’re going to place the TWTR 01/20 $19 and $20 Calls for the time being, with the added caveat that a buyout actually coming to fruition would very likely necessitate an adjustment to our strike prices.


Extended Watchlist:
RIG, SDRL, REXX, CLRB, TOPS, DRYS